Clinical Features of Neuroblastoma With 11q Deletion: An Increase in Relapse Probabilities In Localized And 4S Stages

11q deletion in neuroblastoma: a review of biological and clinical implications

(2017) Vid Mlakar et al.   Molecular Cancer

Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism

(2015) Stefano J. Mandriota et al.   Oncotarget

Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics

(2014) Inge M. Ambros et al.   Frontiers in Oncology

Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation

(2013) Cihan Cetinkaya et al.   BMC CANCER

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

(2012) G Schleiermacher et al.   BRITISH JOURNAL OF CANCER

Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma

(2011) E E Santo et al.   ONCOGENE

Accumulation of Segmental Alterations Determines Progression in Neuroblastoma

(2010) Gudrun Schleiermacher et al.   JOURNAL OF CLINICAL ONCOLOGY

High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset

(2010) H. Caren et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Poor Survival for Infants WithMYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience

(2009) Adela Canete et al.   JOURNAL OF CLINICAL ONCOLOGY

Expression ofTSLC1, a candidate tumor suppressor gene mapped to chromosome 11q23, is downregulated in unfavorable neuroblastoma without promoter hypermethylation

(2008) Kiyohiro Ando et al.   INTERNATIONAL JOURNAL OF CANCER

The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report

(2008) Tom Monclair et al.   JOURNAL OF CLINICAL ONCOLOGY